Your browser is no longer supported. Please, upgrade your browser.
Protagenic Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.31 Insider Own3.60% Shs Outstand10.52M Perf Week16.93%
Market Cap44.55M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.82M Perf Month-1.00%
Income-3.30M PEG- EPS next Q- Inst Own12.20% Short Float3.53% Perf Quarter158.26%
Sales- P/S- EPS this Y-44.50% Inst Trans31.37% Short Ratio0.05 Perf Half Y-82.77%
Book/sh-0.19 P/B- EPS next Y- ROA- Target Price- Perf Year-80.79%
Cash/sh0.01 P/C222.75 EPS next 5Y- ROE- 52W Range1.05 - 7.00 Perf YTD182.86%
Dividend- P/FCF- EPS past 5Y53.40% ROI- 52W High-57.57% Beta-
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low182.86% ATR0.53
Employees- Current Ratio0.30 Sales Q/Q- Oper. Margin- RSI (14)55.42 Volatility22.46% 17.93%
OptionableNo Debt/Eq- EPS Q/Q-136.00% Profit Margin- Rel Volume4.39 Prev Close2.67
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.22M Price2.97
Recom- SMA2026.25% SMA50-16.35% SMA200-61.93% Volume22,892,367 Change11.24%
Apr-29-21 03:06PM  
Apr-26-21 08:58PM  
Dec-16-20 09:15AM  
Sep-08-20 12:10PM  
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.